title: Efficacy of high intensity atorvastatin versus moderate intensity atorvastatin for acute coronary syndrome patients with diabetes mellitus.
abstract: OBJECTIVE
  To investigate whether more benefits can be achieved through high intensity atorvastatin compared with moderate intensity atorvastatin in acute coronary syndrome (ACS) patients with diabetes mellitus (DM).
  
  
  METHODS
  This was a randomized controlled trail. Total 591 ACS patients with DM who underwent percutaneous coronary intervention were enrolled, 297 in high intensity atorvastatin group (40mg/day) and 294 in moderate intensity atorvastatin group (20mg/day). The primary end point was one-year incidence of major adverse cardiovascular events (MACE, including cardiovascular death, spontaneous myocardial infarction, unplanned revascularization). Cox proportional hazard regression models were used to analyze the association between clinical endpoints and atorvastatin treatment.
  
  
  RESULTS
  At the end of one-year, low-density lipoprotein cholesterol level was lower in high intensity group than in moderate group (1.6±0.6 vs 1.8±0.6, p=0.041). MACE in high intensity group decreased 44.5% than moderate group (8.4% vs. 14.6%, p=0.018). The adjusted hazard ratio (HR) for MACE in patients with atorvastatin 40mg/d was lower compared to patients with atorvastatin 20mg/d (HR [95% CI] 0.61 [0.36 to 0.91], p=0.026). The rates of adverse events were no significantly different between the two groups.
  
  
  CONCLUSIONS
  For ACS patients with DM, high intensity atorvastatin induced better long-term outcomes compared with moderate intensity.
authors.affiliation: Division of Cardiology, Xuanwu Hospital Capital Medical University, Beijing, China.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Liu
authors.affiliation: Division of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, China.
authors.forename: Yueqiao
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Division of Cardiology, Xuanwu Hospital Capital Medical University, Beijing, China.
authors.forename: Hengjian
authors.initials: H
authors.lastname: Hao
authors.affiliation: Division of Cardiology, Xuanwu Hospital Capital Medical University, Beijing, China.
authors.forename: Chunlin
authors.initials: C
authors.lastname: Yin
authors.affiliation: Division of Cardiology, Xuanwu Hospital Capital Medical University, Beijing, China.
authors.forename: Ji
authors.initials: J
authors.lastname: Xu
authors.affiliation: Division of Cardiology, Xuanwu Hospital Capital Medical University, Beijing, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.affiliation: Division of Cardiology, Xuanwu Hospital Capital Medical University, Beijing, China.
authors.forename: Yanling
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Division of Cardiology, Xuanwu Hospital Capital Medical University, Beijing, China. Electronic address: xwyy168@sina.com.
authors.forename: Dong
authors.initials: D
authors.lastname: Xu
mesh_terms: D054058:Acute Coronary Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D000368:Aged; D000069059:Atorvastatin / Q000008:administration & dosage / Q000009:adverse effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000069451:Long Term Adverse Effects / Q000175:diagnosis / Q000453:epidemiology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D011379:Prognosis; D016016:Proportional Hazards Models; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000069059:Atorvastatin
keywords: Acute coronary syndrome; Atorvastatin; Diabetes mellitus; Prognosis